On November 22, 2012, Volcano Corporation (the "Company") entered into a share purchase agreement to acquire all of the outstanding equity of Sync-Rx Ltd., a privately-held company based in Israel ("Sync-Rx") that develops advanced software applications designed to optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. Pursuant to the agreement, a wholly-owned Israeli subsidiary of the Company will acquire all of the outstanding equity shares of Sync-Rx for an aggregate purchase price of $17.3 million, minus the amount of transaction expenses and indebtedness of Sync-Rx that remain unpaid at the closing, and subject to a positive or negative working capital adjustment to the extent that Sync-Rx's working capital is greater than or less than zero at the closing. The Company will assume approximately $1.9 million of repayment obligations of Sync-Rx in connection with grants from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor. The transaction has been approved by the boards of directors of both the Company and Sync-Rx. No vote of the Company's stockholders is required in connection with the transaction.

At the closing of the transaction, $3.3 million of the aggregate consideration otherwise payable at closing will be contributed to an escrow account to secure indemnification rights of the Company, which will be available for 18 months to indemnify the Company and related indemnitees for certain matters, including breaches of representations and warranties and covenants included in the share purchase agreement. The Company, Sync-Rx and the shareholders of Sync-Rx have agreed to customary representations and warranties.

Following the closing of the transaction, the Company, through a wholly-owned Israeli subsidiary, will continue the operations of Sync-Rx in Israel. Substantially all of the employees of Sync-Rx are expected to remain as employees following the closing of the transaction, and the Company will maintain an employee retention and performance bonus plan for certain employees and consultants of Sync-Rx.

A copy of the press release announcing the execution of the share agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(d) Exhibits.

    Exhibit
    Number    Description of Exhibit

    99.1      Press Release issued by Volcano Corporation on November 23, 2012

Forward-Looking Statements

This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including: statements regarding the expected closing of the transaction described above; the features and capabilities or potential features and capabilities of the technologies of Sync-Rx; the expected benefits to the Company of the transaction; the complementary nature of the Sync-Rx technologies to be acquired with the Company's business, products and technologies; the expected market, including its size, to be addressed by the Company's products and Sync Rx's products; future operations of the Sync-Rx business; and the benefits or potential benefits of the Company's products and procedures. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include: the risk that the transaction described above is not completed; the risk that the benefits of the transaction described above are not realized; the effect of competitive factors and the Company's reactions to those factors; purchasing decisions with respect to the Company's products; the pace and extent of market adoption of the Company's products and technologies; uncertainty in the process of obtaining regulatory approval or clearance for the Company's products or devices; the success of the Company's growth strategies; risks associated with the Company's international operations; timing and achievement of product development milestones; the outcome of ongoing or future litigation; the impact and benefits of market